Abstracts Archive - Page 2118 of 2425 - ACR Meeting Abstracts

Abstract Number: 1990 • 2013 ACR/ARHP Annual Meeting
Treatment Of ACUTE Gout In The Emergency Department Evaluated According To The 2012 American College Of Rheumatology Guidelines
Naomi Schlesinger¹, Tina Chang Young², Diane C. Radvanski³, Dirk Moore⁴ and Robert Eisenstein⁵, ¹Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Department of Biostatistics, UMDNJ/School of Public Health, Piscataway, NJ, ³Department of Medicine, Division of Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Department of Biostatistics, UMDNJ - School of Public Health, Piscataway, NJ, ⁵, Department of Emergency Medicine, UMDNJ- Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Acute gout attacks account for a substantial number of emergency department (ED) visits. Our aim was to record acute gout treatment in the ED…
Abstract Number: 1993 • 2013 ACR/ARHP Annual Meeting
Geographic Variations Of Gout Epidemiology In The United Kingdom: A Nationwide Population Study
Chang-Fu Kuo^1,2, Michael Doherty³, Matthew J. Grainge⁴ and Weiya Zhang¹, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taipei, Taiwan, ³Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom, ⁴Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: To examine geographic variations of gout prevalence, incidence and management in the United Kingdom. Methods: We used the Clinical Practice Research Data-link (CPRD) to…
Abstract Number: 1994 • 2013 ACR/ARHP Annual Meeting
Performance Of Gout Impact Scale Of The Gout Assessment Questionnaire In a Longitudinal Observational Study Of Patients With Gout
Puja Khanna¹, Cleopatra Aquino-Beaton², Jasvinder A. Singh³, Erin Duffy⁴, David Elashoff⁵ and Dinesh Khanna⁶, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Medicine, University of California Los Angeles, Los Angeles, CA, ⁵Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁶University of Michigan Health System, Ann Arbor, MI
Background/Purpose: Gout Assessment Questionnaire (GAQ2.0) is a validated disease-specific measure used to evaluate patient reported outcomes in gout studies. The objective was to evaluate the…
Abstract Number: 1995 • 2013 ACR/ARHP Annual Meeting
Serum Homocysteine Related To Decreased Renal Function In Chronic Gouty Patients
Jung-Soo Song¹, Jin Su Kim² and Sang Tae Choi¹, ¹Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ²Chung-Ang University College of Medicine, Seoul, South Korea
Background/Purpose: Homocysteine is a non-essential amino acid formed by the conversion of methionine to cysteine. Hyperhomocysteinemia is a risk factor for cardiovascular events by inducing…
Abstract Number: 1996 • 2013 ACR/ARHP Annual Meeting
Racial/Ethnicity Differences In Health-Related Quality Of Life (HRQOL), Functional Ability and Health Care Utilization In Gout Patients
Aseem Bharat¹, Jasvinder A. Singh^2,3, Puja Khanna⁴, Cleopatra Aquino-Beaton⁵, Jay E. Persselin⁶, Erin Duffy⁷, David Elashoff⁸ and Dinesh Khanna⁹, ¹Medicine/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, Birmingham VA, Birmingham, AL, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁶Medicine W-111J Div of Rheum, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁷Medicine, University of California Los Angeles, Los Angeles, CA, ⁸Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: Due to limited/no data for race/ethnicity, our objective was to assess whether HRQOL functional ability and health care utilization in gout patients differs by…
Abstract Number: 1997 • 2013 ACR/ARHP Annual Meeting
Health Care Utilization In Gout Patients: A Prospective Multicenter Cohort Study
Jasvinder A. Singh^1,2, Aseem Bharat³, Puja Khanna⁴, Cleopatra Aquino-Beaton⁵, Jay E. Persselin⁶, Erin Duffy⁷, David Elashoff⁸ and Dinesh Khanna⁹, ¹Rheumatology, Birmingham VA, Birmingham, AL, ²Department of Medicine, University of Alabama, Tuscaloosa, AL, ³Medicine/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁶Medicine W-111J Div of Rheum, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁷Medicine, University of California Los Angeles, Los Angeles, CA, ⁸Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI
Background/Purpose: Because of the chronic nature of the disease, gout is associated with more co-morbidities, poor health-related quality of life (HRQoL) and more healthcare utilization…
Abstract Number: 1998 • 2013 ACR/ARHP Annual Meeting
The Risk Of Subsequent Attacks In Patients With Incident Gout: A Population-Based Study
Nour Zleik¹, Clement J. Michet¹, Helen Khun², Cynthia S. Crowson², Eric L. Matteson¹ and Tim Bongartz¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: While there appears to be consensus that non-pharmacological uric acid lowering therapies (diet and lifestyle modifications) should be initiated in every patient presenting with…
Abstract Number: 1999 • 2013 ACR/ARHP Annual Meeting
Hospitalization and Flare Risk In Patients With Established Gout: A Population-Based Study
Nour Zleik¹, Clement J. Michet¹, Helen Khun², Cynthia S. Crowson², Eric L. Matteson¹ and Tim Bongartz¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Hospitalization of patients with gout may be associated with an increased risk of arthritic flares, due to administration of IV fluids, discontinuation of established…
Abstract Number: 2001 • 2013 ACR/ARHP Annual Meeting
Kaiser Permanent Pyramid In Patients With Gout: The Most Severe Gout Is Associated To The Most Complex Patients
Fernando Perez-Ruiz^1,2, Ana M. Herrero-Beites^1,3 and Amaya Martinez-Galarza^4,5, ¹BioCruces Health Research Institute, Baracaldo, Spain, ²Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ³Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain, ⁴Clinical Investigation Unit, Hospital Universitario Cruces, Baracaldo, Spain, ⁵BioCruces Health Institute, Baracaldo, Spain
Background/Purpose: gout is well known to be associated with comorbid conditions; the Kaiser Permanente Pyramid (KPP) identify high risk people (two higher strata) in the…
Abstract Number: 2002 • 2013 ACR/ARHP Annual Meeting
Prophylactic Duration and Serum Uric Acid Level Are Associated With Gout Flare During Urate Lowering Treatment
Hyo-Jin Choi¹, Chan Hee Lee², Sang Tae Choi³, Jung-Soo Song³, Hyoun-Ah Kim⁴, Chang-Hee Suh⁵, Hoyeon Joo⁶, Ki Chul Shin⁷ and Hanjoo Baek¹, ¹Rheumatology, Gachon University Gil Hospital, Incheon, South Korea, ²Div Rheum Dept of Intl Med, NHIC Ilsan Hospital, Goyang-si, South Korea, ³Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ⁴Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ⁵Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ⁷Rheumatology, Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: To evaluate the clinical factors on gout flare during urate lowering treatment Methods: We retrospectively examined data derived from 228 patients who had been treated…
Abstract Number: 2003 • 2013 ACR/ARHP Annual Meeting
Outcome Of Gout Patients Placed On Febuxostat After Failing To Reach Serum Urate Target With Allopurinol
Hind Hatoum^1,2, Dinesh Khanna³, Aki Shiozawa⁴, Swu-Jane Lin^1,5, Kasem Akhras⁶ and Puja Khanna⁷, ¹Hind T. Hatoum and Company, Chicago, IL, ²University of Illinois at Chicago, chicago, IL, ³Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁵University of Illinois at Chicago, Chicago, IL, ⁶Global Outcomes Research, Formerly of Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁷Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: The 2012 American College of Rheumatology (ACR) gout guidelines recommends allopurinol or febuxostat as first-line urate-lowering therapy (ULT). Purpose of this study was to…
Abstract Number: 2004 • 2013 ACR/ARHP Annual Meeting
Kidney Disease Is An Independent Risk Factor For Incident Gout
Weiqi Wang¹, Vidula Bhole² and Eswar Krishnan³, ¹medicine, stanford university, palo alto, CA, ²EpiSolutions Consultancy Services, Thane, India, ³Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Even though the prevalence of chronic kidney disease (CKD) has been shown to be dispoportionarely high among those with gout, there have been scant…
Abstract Number: 2005 • 2013 ACR/ARHP Annual Meeting
Predictors Of Outcomes In Tophaceous Gout- Results From a Prospective Cohort At The Veterans Affairs
Puja Khanna^1,2, Cleopatra Aquino-Beaton³, Jasvinder A. Singh⁴, Erin Duffy⁵, David Elashoff⁶ and Dinesh Khanna⁷, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Rheumatology, Ann Arbor VA, Ann Arbor, MI, ³Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ⁴Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁵Medicine, University of California Los Angeles, Los Angeles, CA, ⁶Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁷University of Michigan Health System, Ann Arbor, MI
Background/Purpose: Tophaceous gout is a chronic inflammatory arthritis that causes debilitating acute attacks and associated with exponential resource utilization. Our objective was to define predictors…
Abstract Number: 2006 • 2013 ACR/ARHP Annual Meeting
Uric Acid Level Is Not An Independent Predictor Of Cardiovascular Diseases In Gout Patients With Treatment; Long-Term Follow-Up Data In Single Tertiary Center In South Korea
Seulkee Lee¹, Eun-Jung Park², Jinseok Kim³, Chan Hong Jeon⁴, Hyungjin Kim⁵, Jaejoon Lee¹, Eun-Mi Koh¹ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Internal Medicine, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Republic of Korea, Jeju, South Korea, ³Internal Medicine, Jeju National University Hospital, Jeju, South Korea, ⁴Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ⁵Department of medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Hyperuricemia and gout are closely related conditions that are prevalent worldwide. A possible link between hyperuricemia and cardiovascular diseases (CVD) has been a debated…
Abstract Number: 2007 • 2013 ACR/ARHP Annual Meeting
Using Natural Language Processing and Machine Learning To Identify Gout Flares From Electronic Clinical Notes
Chengyi Zheng¹, Nazia Rashid², T. Craig Cheetham³, Yi-Lin Wu³ and Gerald D. Levy⁴, ¹Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ²Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA, ³Pharmacy Analytical Services, Kaiser Permanente, Downey, CA, ⁴Int Med/Rheumatology, Southern California Permanente Medical Group, Downey, CA
Background/Purpose: Gout flares are the most common manifestation of gout. Gout flares are not well documented by diagnosis codes and are not adequately captured when…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].